Eli Lilly Hits $1.2T Market Cap as Zepbound and Mounjaro Demand Crushes Expectations

What’s happening
Eli Lilly stock surged to record highs after reporting stronger-than-expected third-quarter earnings powered by obesity drug Zepbound and diabetes treatment Mounjaro. The company raised sales guidance for the third time this year, pushing its market cap to $1.2 trillion as weight-loss drug demand continues to accelerate.
Market impact
Lilly's dominance in the GLP-1 market is translating into outsized earnings growth and multiple expansion. The stock's resilience reflects investor confidence that obesity and diabetes treatment represents a multi-decade growth runway with limited competitive pressure from Novo Nordisk and Amgen.
Broader implications
Lilly's ascent signals a structural shift in pharma valuations toward metabolic disease treatments, which address massive addressable markets with high pricing power. The company's success also underscores how demographic and lifestyle trends can create generational wealth creation opportunities in healthcare.
Sources (3)
The articles Pulse read to write this story
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge - as market cap hits $1.2 trillionNew York Post BusinessStrong bullish +55- Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.Market WatchStrong bullish +83
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demandCNBC Top StoriesStrong bullish +58
Written by Pulse AI from the articles above. Always check the original reporting before acting on it.

